Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

Cited by (154)

Items 101–154 of 154

1. Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique
   Michèle Reboud‐Ravaux · 2021 · Biologie Aujourd hui
2. Alternative Approaches to Counter Multidrug-Resistant Bacterial Pathogens
   Deepanshi Saxena, Rahul Maitra, Arunava Dasgupta, Sidharth Chopra · 2024 · Springer eBooks
3. Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma
   Xiaoli Yu, Xiang Liao, Jingyu Zhang, Hanlin Wang, Xian Li, Jialiang Lu, Huan Zhou, Mingfei Wu, Yuheng Jin, Xin Jian Zhu et al. · 2025 · Journal of Medicinal Chemistry
4. Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma
   Yuheng Jin, Xiang Liao, Jingyu Zhang, Haiting Duan, Ran Xu, Xiaomin Luo, Xiaoli Yu, Bizhi Li, Jia Wang, Xian Li et al. · 2025 · Journal of Medicinal Chemistry
5. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays
   Olivier A. Pierrat, Manjuan Liu, Gavin W. Collie, Kartika N. Shetty, Matthew J. Rodrigues, Yann‐Vaï Le Bihan, Emma A. Gunnell, Craig McAndrew, Mark Stubbs, Martin Rowlands et al. · 2022 · Scientific Reports
6. Increased slow dynamics defines ligandability of BTB domains
   Vladlena Kharchenko, Brian M. Linhares, Megan Borregard, Iwona Czaban, Jolanta E. Grembecka, Mariusz Jaremko, Tomasz Cierpicki, Łukasz Jaremko · 2022 · Nature Communications
7. Impact of SNPs, off-targets, and passive permeability on efficacy of BCL6 degrading drugs assigned by virtual screening and 3D-QSAR approach
   Solmaz Karimi, Farzaneh Shahabi, Shaden M. H. Mubarak, Hanie Arjmandi, Zahra Sadat Hashemi, Navid Pourzardosht, Alireza Zakeri, Mahdieh Mahboobi, Abolfazl Jahangiri, Mohammad Reza Rahbar et al. · 2022 · Scientific Reports
8. The ZBTB family in cardiac development and diseases
   Xing Xiang, Jie Mao, Dan Tang, Hong Huang, Huifang Tang · 2025 · Biochemical and Biophysical Research Communications
9. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
   Yangping Wu, Jingliao Zhang, Xiaofan Zhu, Yingchi Zhang · 2022 · Cancer Letters
10. PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
    Philipp M. Cromm, Craig M. Crews, Hilmar Weinmann · 2020 · Royal Society of Chemistry eBooks
11. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
    Muhammad Zafar Irshad Khan, Adila Nazli, Youlu Pan, Jian‐Zhong Chen · 2022 · Current Medicinal Chemistry
12. Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC
    Daria Torodii, Jacob Brian Holmes, Manuel Cordova, Pinelopi Moutzouri, Lotte van Beek, Fredrik Edfeldt, Erik Malmerberg, Stig D. Friis, Johan R. Johansson, Alexander G. Milbradt et al. · 2025 · Nature Communications
13. E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
    Bhaskar Basu, Satadeepa Kal, Subhajit Karmakar, Malini Basu, Mrinal K. Ghosh · 2023 · Life Sciences
14. Bicyclic β‐Sheet Mimetics that Target the Transcriptional Coactivator β‐Catenin and Inhibit Wnt Signaling
    Mathias Wendt, Rosa Bellavita, Alan Gerber, Nina‐Louisa Efrém, Thirza van Ramshorst, Nicholas M. Pearce, Paul R. J. Davey, Isabel Everard, Mercedes Vázquez–Chantada, Elisabetta Chiarparin et al. · 2021 · Angewandte Chemie
15. Protein Polymerization as a Novel Targeted Protein Degradation Mechanism
    Raphaëlle Berger, Anthony W. Partridge · 2021 · Biochemistry
16. Borrowing Transcriptional Kinases to Activate Apoptosis
    Roman C. Sarott, Sai P. Gourisankar, Basel A. Karim, Sabin A. Nettles, Haopeng Yang, Brendan G. Dwyer, Juste Simanauskaite, Jason Tse, Hind Z. Abuzaid, A. Krokhotin et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
17. Prospects and advances of PROTAC in the treatment of hematologic malignancies
    Xinyang Wang, Ming Zhang, Heng Mei · 2026 · Experimental Hematology and Oncology
18. B-cell lymphoma 6 in breast cancer: molecular mechanisms and clinical significance
    Frank Louwen, Andreas Ritter, Nina‐Naomi Kreis, Samira Catharina Hoock, Christine Solbach, Juping Yuan · 2025 · Critical Reviews in Biochemistry and Molecular Biology
19. Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase
    Hamidreza Sohbati, Mohsen Amini, Saeed Balalaie · 2022 · Iranian journal of pharmaceutical research
20. Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma Cells
    Yanfeng Wang, Beier Jiang, Yichen Yin, Tao Li, Jing Chen · 2026 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
21. Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets
    Xun Lu, Jianliang Qin, Shuilin Dong, Yue Yuan, Zhanguo Zhang, B Zhang, Xiaoping Chen, Xiaoli Gan, Huifang Liang, Furong Liu · 2026 · Biomarker Research
22. Targeted Protein Degradation by Proteolysis Targeting Chimeras
    Wu Du · 2022
23. Transcription factor degraders
    Manni Wang, Yuhao Wei, Xiaoling Ma · 2025 · Elsevier eBooks
24. Degraders of cell cycle- and antiapoptosis-related proteins
    Yingqiong Zhang, Rong Dong, Bo Zhang · 2025 · Elsevier eBooks
25. BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses
    Rens Kraaijeveld, Dennis Alexander Hesselink, Louisa Steines, Sebastiaan Heidt, Carla C. Baan · 2025 · Frontiers in Immunology
26. Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent
    Rong Hu, Xia-Tong Hu, Ying-Yue Yang, Lingfeng Du, X. LAN, Peng Luo, Cai-Hua Li, Luo-Ting. YU, Ningyu Wang · 2026 · European Journal of Medicinal Chemistry
27. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
    Sunny Periyasamy, Thyla Jarrett, Joe Truong, Rachid Skouta · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
28. Design of Potent and Selective BCL6 Transcriptional Chemical Inducers of Proximity through Linker Optimization
    Fang-Chi Chang, Veronika M. Shoba, Oleh Shyshlyk, Andrii Frolov, Daniil Skrypnik, Halyna Bubela, Yuliia Holota, Corentine M. C. Laurin, Rodrigo A. Rodriguez, C. Avery Sader et al. · 2026 · Journal of Medicinal Chemistry
29. The DNA binding protein BCL6 regulates NFκB-controlled endothelial inflammatory gene expression
    Adriana Franco Acevedo, Julia J. Mack, Nicole M. Valenzuela · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
30. IL-10- and TGF-β-driven BCL6 expression suppresses antiviral defenses and renders lymph node T follicular helper cells permissive to HIV infection
    Susan Pereira Ribeiro, Perla M. Del Río Estrada, Spiros Georgakis, Michail Orfanakis, Alisa A. Omelchenko, Fernanda Caroline Coirada, Jessica Dos Santos, Suzzane Ruijten, Mareva Delporte, Ytse Noppe et al. · 2026 · Research Square
31. Diversity-orientated synthesis of macrocyclic heterocycles using a double S N Ar approach
    Piotr Raubo, Rodrigo J. Carbajo, William McCoull, Joanna Raubo, Morgan C. Thomas · 2021 · Organic & Biomolecular Chemistry
32. New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
    Eric Valeur · 2023 · Royal Society of Chemistry eBooks
33. Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors
    Ahmed Mamai, M. Monzur Morshed, Michael A. Prakesch, Gennady I. Poda, Subramanian Pandiaraju, Anh M. Chau, Iain D. G. Watson, Babu Joseph, Brian Wilson, Justin A. Morin et al. · 2025 · Bioorganic & Medicinal Chemistry Letters
34. A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment
    S H Liu, Xueying Gao, Xuan Ye, Yuehua Chen, K J Wang, Yangsui Liu, S Wang, haorui shen, Hongyu Shen, R J Li et al. · 2026 · Discover Oncology
35. Protein Age Bias in Target Degradation by PROTACs
    Bingbing X. Li, Xiangshu Xiao · 2026 · ACS Chemical Biology
36. The ubiquitin system in normal and infected germinal center B cells
    Destiny Davis, Lesly E. Mejia, Emily K. Moser · 2026 · FEBS Letters
37. Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma
    Xuetao Chen, Rujun Xu, Xiaoran Wang, Huidan Wu, Nan Wang, Xin Huang, Wenjing Kang, Qidong You, Xiaoke Guo, Zhengyu Jiang · 2026 · Journal of Medicinal Chemistry
38. BindingDB Entry 50011291: Monomeric Targeted Protein Degraders.
    BindingDB · 2022 · UC San Diego
39. BindingDB Entry 50010738: Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
    BindingDB · 2021 · UC San Diego
40. BindingDB Entry 50007681: Achieving
    BindingDB · 2021 · UC San Diego
41. BindingDB Entry 11791: Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
    BindingDB · 2024 · UC San Diego
42. BindingDB Entry 50007767: Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    BindingDB · 2021 · UC San Diego
43. BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
    BindingDB · 2024 · UC San Diego
44. BindingDB Entry 50007010: Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.
    BindingDB · 2021 · UC San Diego
45. BindingDB Entry 50016775: Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.
    BindingDB · 2023 · UC San Diego
46. BindingDB Entry 50012845: Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
    BindingDB · 2022 · UC San Diego
47. BindingDB Entry 50017933: Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6
    BindingDB · 2023 · UC San Diego
48. BindingDB Entry 50013984: Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
    BindingDB · 2022 · UC San Diego
49. BindingDB Entry 50015561: Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.
    BindingDB · 2023 · UC San Diego
50. BindingDB Entry 50006562: Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    BindingDB · 2024 · UC San Diego
51. BindingDB Entry 50022214: Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
    BindingDB · 2025 · UC San Diego
52. BindingDB Entry 50010780: Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
    BindingDB · 2021 · UC San Diego
53. BindingDB Entry 50017482: B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
    BindingDB · 2023 · UC San Diego
54. BindingDB Entry 50019405: Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
    BindingDB · 2024 · UC San Diego